Welcome to the international HTA database

Showing [16381 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2022	Agency for Care Effectiveness (ACE)	Regorafenib and trifluridine/tipiracil for previously treated metastatic colorectal cancer
2022	National Institute for Health and Care Excellence (NICE)	Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain. NICE interventional procedures guidance 739
2022	Agency for Care Effectiveness (ACE)	Botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine
2022	National Institute for Health and Care Excellence (NICE)	Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 737
2022	Agency for Care Effectiveness (ACE)	Review of cancer drugs for previously treated advanced hepatocellular carcinoma
2022	National Institute for Health and Care Excellence (NICE)	Removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause. NICE interventional procedures guidance 738
2022	Agency for Care Effectiveness (ACE)	High-strength insulin glargine for treating type 1 and 2 diabetes mellitus
2022	National Institute for Health and Care Excellence (NICE)	Focal resurfacing implants to treat articular cartilage damage in the knee. NICE interventional procedures guidance 734
2022	Agency for Care Effectiveness (ACE)	Bevacizumab for treating persistent, recurrent or metastatic cervical cancer
2022	National Institute for Health and Care Excellence (NICE)	Transcutaneous electrical neuromuscular stimulation for urinary incontinence. NICE interventional procedures guidance 735
2022	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Systematic review of health care interventions in the context of return to work for persons being at risk for long-term sick leave]
2022	Agency for Care Effectiveness (ACE)	Aflibercept, bevacizumab and ramucirumab for treating metastatic colorectal cancer
2022	National Institute for Health and Care Excellence (NICE)	Superficial venous arterialisation for chronic limb threatening ischaemia. NICE interventional procedures guidance 736
2022	Agency for Care Effectiveness (ACE)	Carbonic anhydrase inhibitor eye drops for treating open-angle glaucoma or ocular hypertension
2022	National Institute for Health and Care Excellence (NICE)	Bioresorbable stent implantation to treat coronary artery disease. NICE interventional procedures guidance 732
2022	NIHR Health Technology Assessment programme	Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT
2022	Agency for Care Effectiveness (ACE)	PARP inhibitors and bevacizumab for treating advanced ovarian cancer
2022	National Institute for Health and Care Excellence (NICE)	Aortic remodelling hybrid stent insertion during surgical repair of an acute type A aortic dissection. NICE interventional procedures guidance 733
2022	Agency for Care Effectiveness (ACE)	Bevacizumab biosimilar for treating different types of cancers
2022	National Institute for Health and Care Excellence (NICE)	Transcatheter tricuspid valve annuloplasty for tricuspid regurgitation. NICE interventional procedures guidance 730
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Restrictive red blood cell (RBC) transfusion thresholds: update
2022	Agency for Care Effectiveness (ACE)	Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease
2022	National Institute for Health and Care Excellence (NICE)	Transcatheter tricuspid valve leaflet repair for tricuspid regurgitation. NICE interventional procedures guidance 731
2022	NIHR Health Technology Assessment programme	Dynamic contrast-enhanced CT compared with positron emission tomography CT to characterise solitary pulmonary nodules: the SPUtNIk diagnostic accuracy study and economic modelling
2022	Agency for Care Effectiveness (ACE)	Sitagliptin for treating type 2 diabetes mellitus
2022	National Institute for Health and Care Excellence (NICE)	Vertebral body tethering for idiopathic scoliosis in children and young people. NICE interventional procedures guidance 728
2022	Swiss Federal Office of Public Health (FOPH)	Denosumab (Prolia®) for the treatment of osteoporosis
2022	NIHR Public Health Research (PHR) programme	E-health interventions targeting STIs, sexual risk, substance use and mental health among men who have sex with men: four systematic reviews
2022	Agency for Care Effectiveness (ACE)	Emicizumab prophylaxis for patients with haemophilia A
2022	National Institute for Health and Care Excellence (NICE)	Nerve graft for corneal denervation. NICE interventional procedures guidance 729
2022	Swiss Federal Office of Public Health (FOPH)	Trimonthly vs. monthly use of bone-targeted agents in patients with bone metastases and multiple myeloma
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Folate testing. [Protocol]
2022	National Institute for Health and Care Excellence (NICE)	Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus). NICE interventional procedures guidance 727
2022	Swiss Federal Office of Public Health (FOPH)	Sedative-hypnotic drugs for the treatment of primary chronic insomnia disorder
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Revascularisation versus optimal medical therapy (OMT) for the treatment of chronic coronary syndrome (CCS). [Protocol]
2022	National Institute for Health and Care Excellence (NICE)	Endoanchoring systems in endovascular aortic aneurysm repair. NICE interventional procedures guidance 725
2022	Swiss Federal Office of Public Health (FOPH)	Levothyroxine for patients diagnosed with subclinical hypothyroidism
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Denosumab (Prolia) for the treatment of osteoporosis
2022	National Institute for Health and Care Excellence (NICE)	Supercapsular percutaneously assisted total hip arthroplasty for osteoarthritis. NICE interventional procedures guidance 726
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Calcitonin gene-related peptide antagonists for the prevention of migraine [Protocol]
2022	National Institute for Health and Care Excellence (NICE)	Personalised external aortic root support (PEARS) using mesh to prevent aortic root expansion and aortic dissection in people with Marfan syndrome. NICE interventional procedures guidance 724
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Oral anticoagulants for prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation. [Protocol]
2022	National Institute for Health and Care Excellence (NICE)	Liposuction for chronic lymphoedema. NICE interventional procedures guidance 723
2022	National Institute for Health and Care Excellence (NICE)	Intramedullary distraction for upper limb lengthening. NICE interventional procedures guidance 722
2022	National Institute for Health and Care Excellence (NICE)	Liposuction for chronic lipoedema. NICE interventional procedures guidance 721
2022	NIHR Health Technology Assessment programme	Endovascular stent grafting and open surgical replacement for chronic thoracic aortic aneurysms: a systematic review and prospective cohort study
2022	NIHR Health Technology Assessment programme	Pre-hospital and emergency department treatment of convulsive status epilepticus in adults: an evidence synthesis
2022	National Institute for Health and Care Excellence (NICE)	Percutaneous insertion of a cystic duct stent after cholecystostomy for acute calculous cholecystitis. NICE interventional procedures guidance 720
2022	Health Technology Wales (HTW)	Virtual reality interventions for the management of pain associated with medical procedures
2022	National Institute for Health and Care Excellence (NICE)	Endoscopic full thickness removal of gastrointestinal stromal tumours of the stomach. NICE interventional procedures guidance 717
2022	NIHR Health Technology Assessment programme	A large randomised assessment of the relative cost-effectiveness of different classes of drugs for Parkinson's disease (PD MED)
2022	National Institute for Health and Care Excellence (NICE)	Intramedullary distraction for lower limb lengthening. NICE interventional procedures guidance 718
2022	Agency for Care Effectiveness (ACE)	Negative pressure wound therapy for wound management in patients with diabetes (type 1 and 2)
2022	National Institute for Health and Care Excellence (NICE)	Endoscopic balloon dilation for subglottic or tracheal stenosis. NICE interventional procedures guidance 719
2022	NIHR Health Technology Assessment programme	Telaprevir for the treatment of genotype 1 chronic hepatitis C
2022	NIHR Health Technology Assessment programme	Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial
2022	Agency for Care Effectiveness (ACE)	Brentuximab vedotin for treating T-cell lymphoma
2022	National Institute for Health and Care Excellence (NICE)	Stereotactic radiosurgery for trigeminal neuralgia. NICE interventional procedures guidance 715
2022	Agency for Care Effectiveness (ACE)	Review of cancer drugs for treating advanced urothelial carcinoma
2022	National Institute for Health and Care Excellence (NICE)	Microwave ablation for primary or metastatic cancer in the lung. NICE interventional procedures guidance 716
2022	Agency for Care Effectiveness (ACE)	Ruxolitinib for treating polycythaemia vera
2022	Agency for Care Effectiveness (ACE)	Review of cancer drugs for treating early or advanced HER2-positive breast cancer
2022	Health Information and Quality Authority (HIQA)	Descriptive analysis of COVID-19 epidemiological indicators and associated contextual factors in European countries
2022	Agency for Care Effectiveness (ACE)	Poly (ADP-ribose) polymerase inhibitors for treating BRCA-mutated, HER2-negative advanced breast cancer
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Blinatumomab (new therapeutic indication: acute lymphoblastic B-cell leukaemia, high-risk first relapse, Ph-, CD19+, ≥1 and <18 years)]
2022	Agency for Care Effectiveness (ACE)	Polatuzumab vedotin for treating relapsed or refractory diffuse large B-cell lymphoma
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Pegcetacoplan (paroxysmal nocturnal haemoglobinuria, pretreated patients)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Migalastat (new therapeutic indication: Fabry disease, 12 to < 16 years)]
2022	Agency for Care Effectiveness (ACE)	Daratumumab-based regimens for newly diagnosed multiple myeloma
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Microwave ablation for liver tumours
2022	The Federal Joint Committee (G-BA)	Pharmaceutical Directive/Annex XII: Odevixibat (progressive familial intrahepatic cholestasis)
2022	Agency for Care Effectiveness (ACE)	Acalabrutinib, bortezomib and ibrutinib for treating mantle cell lymphoma
2022	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Hepatic and portal vein embolization prior to major hepatectomy
2022	Agency for Care Effectiveness (ACE)	Review of cancer drugs for chronic lymphocytic leukaemia
2022	Agency for Care Effectiveness (ACE)	Osimertinib for treating EGFR mutation-positive non-small-cell lung cancer
2022	Norwegian Institute of Public Health (NIPH)	Molecular tests for detection of PIK3CA mutations in men and postmenopausal women with HR+/HER2–, locally advanced or metastatic breast cancer: a health technology assessment
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tafasitamab (diffuse large B-cell lymphoma (DLBCL), combination with lenalidomide)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Selumetinib (neurofibromatosis (≥ 3 to < 18 years, type 1))]
2022	Norwegian Institute of Public Health (NIPH)	Zephyr® valves system in the treatment of emphysema: a single technology assessment
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Vosoritide (achondroplasia, ≥ 2 years)]
2022	Agency for Care Effectiveness (ACE)	Cooral System for the prevention of oral mucositis
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Breast cancer risk assessment tools
2022	Agency for Care Effectiveness (ACE)	Magnetic resonance image guided radiation therapy for patients with cancer
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Testosterone reference ranges for gender diverse individuals
2022	Agency for Care Effectiveness (ACE)	Robot-assisted endovascular intervention systems for coronary artery disease and other vascular diseases
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Structured screening questionnaires for alcohol misuse/alcohol use disorders
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Home-based oral nutritional supplements in cancer patients who require modification of the usual ordinary diet due to mucositis]
2022	Agency for Care Effectiveness (ACE)	Nicotine replacement therapies to aid smoking cessation
2022	Agency for Care Effectiveness (ACE)	Ciclosporin 0.1% eye drops for treating severe keratitis in dry eye disease
2022	Agency for Care Effectiveness (ACE)	Sodium zirconium cyclosilicate for treating hyperkalaemia
2022	Agency for Care Effectiveness (ACE)	Dolutegravir with lamivudine for treating Human Immunodeficiency Virus type 1 (HIV-1) infection
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Clinical utility of inpatient fall risk assessment
2022	Agency for Care Effectiveness (ACE)	Acarbose for treating type 2 diabetes mellitus
2022	Agency for Care Effectiveness (ACE)	Ciclosporin 0.1% eye drops for treating severe vernal keratoconjunctivitis
2022	Norwegian Institute of Public Health (NIPH)	Tests for the detection of NTRK gene fusions in patients with locally advanced or metastatic solid tumours
2022	Agency for Care Effectiveness (ACE)	Recombinant blood products for prophylaxis and management of haemophilia A and B
2022	Austrian Institute for Health Technology Assessment (AIHTA)	CAR-T cell-therapies in development, update 2022
2022	Agency for Care Effectiveness (ACE)	GLP-1 receptor agonist injections for treating type 2 diabetes mellitus
2022	Austrian Institute for Health Technology Assessment (AIHTA)	Regulation and financing of prenatal screening and diagnostic examinations for fetal anomalies in selected European countries
2022	NIHR Health Technology Assessment programme	Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework